PRPH ProPhase Labs Inc

ProPhase Labs to Provide COVID-19 Testing for Oyster Bay Township in New York

ProPhase Labs to Provide COVID-19 Testing for Oyster Bay Township in New York

ProPhase Labs Will Offer State-Of-The-Art Testing to Aid Oyster Bay Community in Reopening

GARDEN CITY, NY, April 22, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: PRPH), a diversified medical science and technology company, today announced that it has been awarded and signed a contract with The Town of Oyster Bay, New York, to provide reliable COVID-19 testing. The contract was awarded after a competitive process where ProPhase Labs demonstrated its COVID-19 testing capabilities, including its accurate and reliable test offerings and fast turnaround times. The Oyster Bay Township, located in Nassau County, encompasses 36 villages and hamlets and nearly 300,000 residents.

This partnership will help bring COVID-19 testing to thousands of Oyster Bay residents, ensuring a safe and controlled reopening for the township. The Town of Oyster Bay will offer ProPhase Labs’ saliva-based, viral RT-PCR multiplex-testing, a type of test proven to quickly detect and identify COVID-19 and any of its 17+ current viral mutations. With labs in both Garden City, New York and Old Bridge, New Jersey, ProPhase Labs has the capacity to provide test results to individuals within 24 hours from the time when one of its labs receives and accepts a specimen.

“We are incredibly happy to partner with The Town of Oyster Bay in their tremendous efforts to combat this virus and get residents back to ‘normal life’,” said Ted Karkus CEO of ProPhase Labs. “The Town of Oyster Bay joins the growing list of healthcare providers, organizations and municipalities that have selected ProPhase Labs for their COVID-19 testing needs. Our fast turnaround times and dependable testing solutions continue to be reasons why ProPhase Labs is selected as a testing partner.”

The roll out will begin with a focus on testing for school students and faculty. ProPhase Labs will also provide testing for major school events this year, such as graduations, proms, and homecomings. Additionally, testing will be offered to municipal employees and the general public in the weeks ahead.

Oyster Bay Town Supervisor Joseph Saladino stated, “The Oyster Bay Town Board recently retained the services of ProPhase Labs with the goal of helping our residents get back to the things they enjoy most in life. From graduation ceremonies to classroom activities and athletic fields, the Town of Oyster Bay is first committed to helping students get back to normal as quickly as possible. In the coming weeks, we will expand eligibility to all residents so that families and seniors looking to attend a concert, dance at a wedding or simply get on a flight, can do so easily by accessing non-invasive COVID testing and obtain quick results.”

About ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company. The Company’s laboratory testing subsidiary, ProPhase Diagnostics, offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through both saliva and nasal swab methods at its CLIA certified laboratories. ProPhase Diagnostics also provides Respiratory Pathogen Panel (RPP) Molecular tests including Influenza A and B and others. ProPhase Labs researches, develops, manufactures, distributes, markets and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. The Company actively pursues strategic investments and acquisition opportunities for other companies, technologies and products. For more information, visit .

Investor Contact

Chris Tyson

Managing Director

MZ Group - MZ North America

949-491-8235



Media Contact:

5W Public Relations

212-999-5585



EN
22/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProPhase Labs Inc

 PRESS RELEASE

ProPhase Labs Announces Financial Results for the Three and Six Months...

ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a diversified diagnostics,...

 PRESS RELEASE

ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Paten...

ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett’s esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart™ test validation (>95% technical success) and, together with BE-Smart’s demonstrated compatibility with both brush and forceps biopsies, supports earlier detection. UNIONDALE, NY, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (the “Company” or “ProPh...

 PRESS RELEASE

ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on...

ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025 UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and...

 PRESS RELEASE

ProPhase Labs Announces Special Meeting of Shareholders and Filing of ...

ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement Proxy Sets Company on a Path to Attract the Optimal Crypto Treasury Strategy Increase in Authorized Shares to 1 Billion Would Position the Company to Attract Industry-Leading Market Participants and High-Value Crypto Treasury Transactions UNIONDALE, NY, July 29, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, will hold a Special Meeting of Shareholders on August 29, 2025, at 4:00 p....

 PRESS RELEASE

ProPhase Labs Announces Closing of $3 Million Senior Secured Convertib...

ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing Financing provides bridge to multiple potentially significant liquidity events and crypto strategies UNIONDALE, NY, July 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the "Company" or "ProPhase") today announced the closing of a private placement financing with two investors for $3 million in senior secured convertible notes with accompanying warrants to purchase shares of common stock. The notes were issued with a 20% original issue discount, are secured by the Company and subsi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch